Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telpegfilgrastim vs Filgrastim for Secondary Prevention of Chemotherapy-Induced Neutropenia in Children and Adolescents
NCT06926751Phase 2Recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Jun 2025
- Primary completion
- Apr 2027
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pegfilgrastim in chemotherapy-induced neutropenia (CIN), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Started Jun 2025; status: recruiting.
02
Drugs
pegfilgrastim
03
Conditions
chemotherapy-induced neutropenia (CIN)
Beyond the preview
Go deeper on NCT06926751.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06926751.